Use of tumour-responsive T cells as cancer treatment.
Use of tumour-responsive T cells as cancer treatment.
复制标题
DOI：
10.1016/s0140-6736(09)60404-9
复制
发表时间：
2009-02-21
期刊：
影响因子：
168.9
通讯作者：
Jaffee, Elizabeth M.
中科院分区：
文献类型：
--
作者：
Disis, Mary L.;Bernhard, Helga;Jaffee, Elizabeth M.
与其他形式的癌症治疗相比，刺激肿瘤特异性T细胞反应有几个理论上的优势。首先，无论T细胞位于体内的什么位置--甚至在深层组织床中--都可以在表达抗原的肿瘤沉积中安家。此外，T细胞可以继续增殖，以回应在癌症中表达的免疫原性蛋白，直到所有的肿瘤细胞被根除。最后，可以产生免疫记忆，如果携带抗原的肿瘤再次发生，就可以根除它们。我们将重点介绍两种刺激肿瘤特异性T细胞免疫的直接方法：用癌症疫苗主动免疫和通过过继T细胞治疗注入有能力的T细胞。临床前和临床研究表明，调节肿瘤微环境以支持免疫反应与刺激最合适的效应T细胞一样重要。T细胞免疫刺激治疗癌症的未来将需要针对肿瘤和T细胞的组合方法。
The stimulation of a tumour-specific T-cell response has several theoretical advantages over other forms of cancer treatment. First, T cells can home in to antigen-expressing tumour deposits no matter where they are located in the body—even in deep tissue beds. Additionally, T cells can continue to proliferate in response to immunogenic proteins expressed in cancer until all the tumour cells are eradicated. Finally, immunological memory can be generated, allowing for eradication of antigen-bearing tumours if they reoccur. We will highlight two direct methods of stimulating tumour-specific T-cell immunity: active immunisation with cancer vaccines and infusion of competent T cells via adoptive T-cell treatment. Preclinical and clinical studies have shown that modulation of the tumour microenvironment to support the immune response is as important as stimulation of the most appropriate effector T cells. The future of T-cell immunity stimulation to treat cancer will need combination approaches focused on both the tumour and the T cell.